Diagnostics of hereditary cancer syndromes by ngs. A database creation experience

Autor: Ivan S. Abramov, Tatyana S. Lisitsa, Anna M. Stroganova, Oxana O. Ryabaya, Anastasiya M. Danishevich, Anastasia O. Khakhina, Anastasiya I. Zakamornaya, Alina D. Matsvay, German A. Shipulin

Publikováno v: Клиническая практика, Vol 12, Iss 3, Pp 36-42 (2021)

Background: More than 500 thousand new cases of malignant neoplasms are registered annually in the Russian Federation, of which more than 50 thousand new cases are due to hereditary forms. Improving the diagnosis of these diseases will make it possib

Externí odkaz: https://doaj.org/article/e83809ec410d427c912b8af02e00473f

Low-toxic multi-liposomal containers for encapsulation of bioactive compounds

Autor: O. A. Novoskol’tseva, Oxana O. Ryabaya, Natalia V. Pozdniakova, Alexander A. Yaroslavov

Publikováno v: Colloids and Surfaces A: Physicochemical and Engineering Aspects. 603:125282

Multi-liposomal assemblies have been prepared via electrostatic adsorption of cationic polylysine over anionic alginate microgels followed by adsorption of anionic liposomes over the polylysine layer. The adsorbed liposomes (up to 150 per one assembl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea75f6ef8e01517a3a48c7fb503effbe
https://doi.org/10.1016/j.colsurfa.2020.125282

The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.

Autor: Ammour Y; I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia., Ryabaya O; N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, 115478, Moscow, Russia., Shchetinina Y; I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia., Prokofeva E; I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia., Gavrilova M; I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia., Khochenkov D; N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, 115478, Moscow, Russia.; Medicinal Chemistry Center, Togliatti State University, 445020 Togliatti, Russia., Vorobyev D; I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, 119146 Moscow, Russia., Faizuloev E; I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia., Shohin I; I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.; Institute of biochemical technology and nanotechnology, RUDN University, 117198 Moscow, Russia., Zverev VV; I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, 119146 Moscow, Russia., Svitich O; I.I. Mechnikov Research Institute for Vaccines and Sera, 105064 Moscow, Russia.; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, 119146 Moscow, Russia., Nasedkina T; Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 119991 Moscow, Russia.

Publikováno v: Viruses [Viruses] 2020 Feb 04; Vol. 12 (2). Date of Electronic Publication: 2020 Feb 04.

Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells.

Autor: Ryabaya O; Department of Experimental Diagnostic and Tumor Therapy N.N. Blokhin National Medical Research Center for Oncology, 115478, 24 Kashirskoe shosse, Moscow, Russia. Electronic address: oxa2601@yandex.ru., Prokofieva A; Department of Experimental Diagnostic and Tumor Therapy N.N. Blokhin National Medical Research Center for Oncology, 115478, 24 Kashirskoe shosse, Moscow, Russia. Electronic address: nastia29mal@mail.ru., Akasov R; Institute of Molecular Medicine Sechenov First Moscow State Medical University, 119991, 8-2 Trubetskaya street, Moscow, Russia; Cytomed J.S.Co, Russia; Federal Scientific Research Center «Crystallography and Photonics» Russian Academy of Sciences, 117997, 17a Butlerova st, Moscow, Russia. Electronic address: roman.akasov@gmail.com., Khochenkov D; Department of Experimental Diagnostic and Tumor Therapy N.N. Blokhin National Medical Research Center for Oncology, 115478, 24 Kashirskoe shosse, Moscow, Russia. Electronic address: khochenkov@gmail.com., Emelyanova M; Department of Biological Microchips Engelhardt Institute of Molecular Biology, 119991, 32 Vavilova street, Moscow, Russia. Electronic address: emel_marina@mail.ru., Burov S; Cytomed J.S.Co, Russia. Electronic address: burov@hq.macro.ru., Markvicheva E; Department of Biomaterials and Biotechnologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia. Electronic address: lemarkv@hotmail.com., Inshakov A; Department of Experimental Diagnostic and Tumor Therapy N.N. Blokhin National Medical Research Center for Oncology, 115478, 24 Kashirskoe shosse, Moscow, Russia. Electronic address: an-inshakov@yandex.ru., Stepanova E; Department of Experimental Diagnostic and Tumor Therapy N.N. Blokhin National Medical Research Center for Oncology, 115478, 24 Kashirskoe shosse, Moscow, Russia. Electronic address: stepanova.rosc@gmail.com.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2019 Jan; Vol. 109, pp. 2548-2560. Date of Electronic Publication: 2018 Dec 05.

Detection of BRAF , NRAS , KIT , GNAQ , GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis.

Autor: Emelyanova M; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation., Ghukasyan L; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation., Abramov I; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation.; Blokhin Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation., Ryabaya O; Blokhin Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation., Stepanova E; Blokhin Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation., Kudryavtseva A; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation.; P. Hertsen Moscow Oncology Research Institute, Moscow, Russian Federation., Sadritdinova A; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation.; P. Hertsen Moscow Oncology Research Institute, Moscow, Russian Federation., Dzhumakova C; Blokhin Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation., Belysheva T; Blokhin Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation., Surzhikov S; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation., Lyubchenko L; Blokhin Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation., Zasedatelev A; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation.; Blokhin Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation., Nasedkina T; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation.; Blokhin Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation.

Publikováno v: Oncotarget [Oncotarget] 2017 Apr 10; Vol. 8 (32), pp. 52304-52320. Date of Electronic Publication: 2017 Apr 10 (Print Publication: 2017).